|
JP7871189B2
(ja)
*
|
2019-12-17 |
2026-06-08 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
タンパク質の動員および／または分解を調節する化合物
|
|
CN122562781A
(zh)
*
|
2020-10-07 |
2026-08-14 |
上海睿跃生物科技有限公司 |
治疗癌症的化合物和方法
|
|
CN117242060B
(zh)
*
|
2021-01-13 |
2026-07-17 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮化合物
|
|
WO2022152822A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Treatment of myc-driven cancers with gspt1 degraders
|
|
WO2022153220A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Methods for the identification of degrons
|
|
EP4313047A1
(en)
*
|
2021-03-22 |
2024-02-07 |
Monte Rosa Therapeutics, Inc. |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
|
US20240287573A1
(en)
|
2021-06-04 |
2024-08-29 |
Monte Rosa Therapeutics, Inc. |
E3 ligase fusion proteins for proximity detection
|
|
CN115504963A
(zh)
*
|
2021-06-22 |
2022-12-23 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白降解剂
|
|
WO2023001028A1
(zh)
*
|
2021-07-19 |
2023-01-26 |
南京明德新药研发有限公司 |
杂芳-3-哌啶二酮类化合物及其应用
|
|
WO2023069720A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and methods of use thereof
|
|
WO2023069708A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and uses thereof
|
|
WO2023069700A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and methods of use thereof
|
|
WO2023069731A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and methods of use thereof
|
|
WO2023091567A1
(en)
|
2021-11-17 |
2023-05-25 |
Monte Rosa Therapeutics, Inc. |
Degron and neosubstrate identification
|
|
EP4508044A1
(en)
|
2022-04-14 |
2025-02-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
EP4554581A1
(en)
|
2022-07-13 |
2025-05-21 |
Monte Rosa Therapeutics AG |
Combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors
|
|
CN119630648A
(zh)
*
|
2022-07-14 |
2025-03-14 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮衍生物的制备方法及其晶形
|
|
WO2024027795A1
(zh)
*
|
2022-08-04 |
2024-02-08 |
苏州开拓药业股份有限公司 |
包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
|
|
CN115636811A
(zh)
*
|
2022-08-17 |
2023-01-24 |
成都分迪药业有限公司 |
异吲哚啉苄胺衍生物的合成方法
|
|
JP2025531869A
(ja)
|
2022-09-09 |
2025-09-25 |
イノヴォ セラピューティクス、インコーポレイテッド |
ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
|
|
KR20260005248A
(ko)
*
|
2023-03-24 |
2026-01-09 |
주식회사 핀테라퓨틱스 |
Gspt1 분해 화합물 및 분해 방법
|
|
WO2025051180A1
(zh)
*
|
2023-09-06 |
2025-03-13 |
上海超阳药业有限公司 |
内酰胺类衍生物及其应用
|
|
KR20260094777A
(ko)
*
|
2023-10-16 |
2026-06-23 |
브리스톨-마이어스 스큅 컴퍼니 |
Gspt1 화합물 및 상기 화합물의 사용 방법
|
|
WO2025146112A1
(en)
*
|
2024-01-05 |
2025-07-10 |
Primelink Biotherapeutics (Shenzhen) Co., Ltd. |
Gspt1 degrading compounds and compositions and uses thereof
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025259615A1
(en)
*
|
2024-06-11 |
2025-12-18 |
Triana Biomedicines, Inc. |
Modulators of cdk2 and uses thereof
|
|
WO2026007898A1
(zh)
*
|
2024-07-01 |
2026-01-08 |
上海海雁医药科技有限公司 |
含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用
|
|
WO2026060296A2
(en)
*
|
2024-09-13 |
2026-03-19 |
Uab Research Foundation |
Compounds for the treatment of cystic fibrosis
|
|
WO2026154063A1
(en)
|
2025-01-16 |
2026-07-23 |
Monte Rosa Therapeutics Ag |
Reverse turboid
|